-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ecnoglutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ecnoglutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ecnoglutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: XW-003 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ecnoglutide in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ecnoglutide in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ecnoglutide in Obesity Drug Details: XW-003 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ecnoglutide in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ecnoglutide in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ecnoglutide in Type 2 Diabetes Drug Details: XW-003 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YPEG-Somatropin in Turner Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YPEG-Somatropin in Turner Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YPEG-Somatropin in Turner Syndrome Drug Details: YPEG-somatropin is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Esmethadone Hydrochloride in Renal Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esmethadone Hydrochloride in Renal Failure report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esmethadone Hydrochloride in Renal Failure Drug Details: REL-1017 (D-methadone) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ivospemin Hydrochloride in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivospemin Hydrochloride in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivospemin Hydrochloride in Pancreatic Ductal Adenocarcinoma Drug Details: Ivospemin hydrochloride...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLR-2007 in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GLR-2007 in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GLR-2007 in Metastatic Brain Tumor Drug Details: GLR-2007 is under development...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2023’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XW-014 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XW-014 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XW-014 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: XW-014 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XW-014 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XW-014 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XW-014 in Type 2 Diabetes Drug Details: XW-014 is under development...